Loading clinical trials...
Loading clinical trials...
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, PK/PD, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
Conditions
Interventions
KT-413
Locations
8
United States
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Henry Ford Health System
Detroit, Michigan, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
MD Anderson Cancer Center
Houston, Texas, United States
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, United States
Start Date
June 13, 2022
Primary Completion Date
July 28, 2023
Completion Date
July 28, 2023
Last Updated
December 10, 2024
NCT03050268
NCT06870760
NCT07260812
NCT05139017
NCT05529069
NCT05006716
Lead Sponsor
Kymera Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions